RATIONALE: Development of new drugs for treatment of Alzheimer's disease (AD) requires valid paradigms for testing their efficacy and sensitive tests validated in translational research. OBJECTIVES: We present validation of a place-navigation task, a Hidden Goal Task (HGT) based on the Morris water maze (MWM), in comparable animal and human protocols. METHODS: We used scopolamine to model cognitive dysfunction similar to that seen in AD and donepezil, a symptomatic medication for AD, to assess its potential reversible effect on this scopolamine-induced cognitive dysfunction. We tested the effects of scopolamine and the combination of scopolamine and donepezil on place navigation and compared their effects in human and rat versions of the HGT. Place navigation testing consisted of 4 sessions of HGT performed at baseline, 2, 4, and 8 h after dosing in humans or 1, 2.5, and 5 h in rats. RESULTS: Scopolamine worsened performance in both animals and humans. In the animal experiment, co-administration of donepezil alleviated the negative effect of scopolamine. In the human experiment, subjects co-administered with scopolamine and donepezil performed similarly to subjects on placebo and scopolamine, indicating a partial ameliorative effect of donepezil. CONCLUSIONS: In the task based on the MWM, scopolamine impaired place navigation, while co-administration of donepezil alleviated this effect in comparable animal and human protocols. Using scopolamine and donepezil to challenge place navigation testing can be studied concurrently in animals and humans and may be a valid and reliable model for translational research, as well as for preclinical and clinical phases of drug trials.

Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Uvalu 84 150 06 Prague Czech Republic

Department of Neurophysiology of Memory Institute of Physiology Academy of Sciences of the Czech Republic Videnska 1083 142 20 Prague Czech Republic

Department of Pharmaceutical Technology Faculty of Pharmacy Charles University Prague Akademika Heyrovskeho 1203 500 05 Hradec Králové Czech Republic

Imperial College Faculty of Medicine South Kensington Campus London SW7 2AZ UK

International Clinical Research Center St Anne's University Hospital Brno Pekarska 53 656 91 Brno Czech Republic

Metis Cognition Ltd Park House Kilmington Common Warminster Wiltshire BA12 6QY UK

National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic

NeuroScios GmbH Willersdorferstrasse 6 A 8061 Radegund Graz Austria

Zobrazit více v PubMed

Neuropsychobiology. 2003;48(2):87-94 PubMed

Brain Res Brain Res Rev. 2001 Aug;36(1):60-90 PubMed

Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101 PubMed

Neurodegener Dis. 2014;13(2-3):192-6 PubMed

Neuropsychologia. 2008 Aug;46(10):2476-84 PubMed

Neurosci Lett. 2007 Jul 18;422(3):169-74 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 1998 Jan;22(1):211-28 PubMed

Alzheimers Dement. 2014 Mar;10 (2):262-7 PubMed

Behav Brain Res. 2005 Apr 30;159(2):175-86 PubMed

Behav Brain Res. 2015 Oct 1;292:1-9 PubMed

Methods Find Exp Clin Pharmacol. 2000 Mar;22(2):89-95 PubMed

FASEB J. 2008 Mar;22(3):659-61 PubMed

Alzheimers Res Ther. 2013 Nov 21;5(6):58 PubMed

J Neurosci Methods. 1984 May;11(1):47-60 PubMed

J Neural Transm (Vienna). 2002 Jul;109(7-8):1067-80 PubMed

J Cereb Blood Flow Metab. 1992 Jan;12 (1):147-54 PubMed

Arch Neurol. 2000 Jan;57(1):94-9 PubMed

Acta Pharmacol Sin. 2002 Apr;23(4):355-60 PubMed

J Psychopharmacol. 2011 Sep;25(9):1256-65 PubMed

Nature. 2011 Sep 28;478(7368):246-9 PubMed

Front Behav Neurosci. 2014 Apr 01;8:106 PubMed

Aviat Space Environ Med. 1991 Jun;62(6):521-6 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):665-76 PubMed

Pharmacol Biochem Behav. 1992 Dec;43(4):1161-4 PubMed

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2590-4 PubMed

Front Behav Neurosci. 2014 Mar 17;8:89 PubMed

Science. 1982 Mar 5;215(4537):1237-9 PubMed

Int J Neuropsychopharmacol. 2006 Apr;9(2):175-89 PubMed

Eur J Pharmacol. 2005 Aug 22;518(2-3):140-4 PubMed

Physiol Behav. 2013 Aug 15;120:11-8 PubMed

Physiol Behav. 1989 Sep;46(3):347-53 PubMed

Behav Neurosci. 2003 Jun;117(3):526-39 PubMed

Behav Neurosci. 1996 Jun;110(3):460-7 PubMed

Aging Clin Exp Res. 2006 Apr;18(2):158-62 PubMed

Neuroscience. 2015 Apr 2;290:530-42 PubMed

J Neurosci. 2003 Jul 2;23(13):5945-52 PubMed

Alzheimers Dement. 2005 Oct;1(2):126-35 PubMed

Nat Commun. 2013;4:2760 PubMed

Neuropsychology. 2014 Sep;28(5):676-84 PubMed

Neuroscience. 2007 May 25;146(3):875-89 PubMed

Alzheimers Dement. 2011 May;7(3):270-9 PubMed

Eur J Neurosci. 2007 Mar;25(5):1581-8 PubMed

Neurology. 2001 Aug 14;57(3):489-95 PubMed

Neurochem Res. 2013 Aug;38(8):1704-14 PubMed

Psychopharmacology (Berl). 2008 Aug;199(3):481-94 PubMed

Psychopharmacology (Berl). 2006 Nov;188(4):629-40 PubMed

Psychopharmacology (Berl). 1997 Nov;134(1):95-106 PubMed

Eur Arch Psychiatry Clin Neurosci. 2010 Nov;260 Suppl 2:S106-10 PubMed

Neurodegener Dis. 2012;10(1-4):153-7 PubMed

Behav Brain Res. 2005 Jun 20;161(2):238-44 PubMed

Biol Psychol. 2006 Jul;73(1):3-18 PubMed

J Psychopharmacol. 1992 Jan;6(4):489-500 PubMed

Hum Psychopharmacol. 2008 Jul;23(5):425-36 PubMed

Neurobiol Learn Mem. 2001 Mar;75(2):190-213 PubMed

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4042-7 PubMed

Cyberpsychol Behav. 2009 Apr;12(2):169-74 PubMed

Neurobiol Aging. 2015 Oct;36(10):2709-15 PubMed

Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat

Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation